首页> 外文期刊>Expert opinion on biological therapy >Engineering blood vessels by gene and cell therapy.
【24h】

Engineering blood vessels by gene and cell therapy.

机译:通过基因和细胞疗法来工程化血管。

获取原文
获取原文并翻译 | 示例
           

摘要

Cardiovascular-related syndromes are the leading cause of morbidity and mortality worldwide. Arterial narrowing and blockage due to atherosclerosis cause reduced blood flow to the brain, heart and legs. Bypass surgery to improve blood flow to the heart and legs in these patients is performed in hundreds of thousands of patients every year. Autologous grafts, such as the internal thoracic artery and saphenous vein, are used in most patients, but in a significant number of patients such grafts are not available and synthetic grafts are used. Synthetic grafts have higher failure rates than autologous grafts due to thrombosis and scar formation within graft lumen. Cell and gene therapy combined with tissue engineering hold a great promise to provide grafts that will be biocompatible and durable. This review describes the field of vascular grafts in the context of tissue engineering using cell and gene therapies.
机译:心血管相关综合征是全世界发病率和死亡率的主要原因。动脉粥样硬化引起的动脉狭窄和阻塞会导致流向大脑,心脏和腿部的血液减少。每年有成千上万的患者进行旁路手术以改善这些患者的心脏和腿部血液流动。在大多数患者中使用自体移植物,例如胸内动脉和大隐静脉,但是在很多患者中,此类移植物不可用,而使用合成移植物。由于血栓形成和内腔瘢痕形成,合成移植物的失败率高于自体移植物。细胞和基因疗法与组织工程相结合,有望提供具有生物相容性和耐用性的移植物。这篇综述描述了在使用细胞和基因疗法的组织工程中脉管移植的领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号